NICE recommends aflibercept for AMD

New guidance from NICE approves the use of aflibercept (Eylea) in patients with wet age-related macular degeneration (AMD).

In two double-blind, phase III studies, the safety profile of aflibercept was comparable to that of ranibizumab, with similar rates of both ocular and non-ocular adverse events.
In two double-blind, phase III studies, the safety profile of aflibercept was comparable to that of ranibizumab, with similar rates of both ocular and non-ocular adverse events.

The use of aflibercept (Eylea) has the same restrictions as ranibizumab when used for the treatment of wet AMD, specifically the following criteria must apply in the eye to be treated:

  • the best-corrected visual acuity is between 6/12 and 6/96
  • there is no permanent structural damage to the fovea
  • the lesion size is no larger than 12 disc areas in greatest linear dimension
  • there is evidence of recent presumed disease progression (blood vessel growth, as indicated by fluorescein angiography, or recent visual acuity changes)

The drug must be provided by the manufacturer with the discount as agreed in the patient access scheme.

View Eylea drug record

NICE guidance on aflibercept solution for injection for treating wet age-related macular degeneration

Follow MIMS on Twitter


MIMS Clinics

Prescribing news and resources for key therapeutic areas, collated by the MIMS editors.

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases

Promo Image

Clinical calculators

Handy calculators and conversions for primary care.